- Home
- ERAS vs ATRO Comparison
ERAS vs ATRO Comparison
Compare ERAS & ATRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- ATRO
- Stock Information
- Founded
- ERAS 2018
- ATRO 1968
- Country
- ERAS United States
- ATRO United States
- Employees
- ERAS N/A
- ATRO N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- ATRO Military/Government/Technical
- Sector
- ERAS Health Care
- ATRO Industrials
- Exchange
- ERAS Nasdaq
- ATRO Nasdaq
- Market Cap
- ERAS 723.8M
- ATRO 591.7M
- IPO Year
- ERAS 2021
- ATRO N/A
- Fundamental
- Price
- ERAS $2.47
- ATRO $15.81
- Analyst Decision
- ERAS Strong Buy
- ATRO Hold
- Analyst Count
- ERAS 5
- ATRO 1
- Target Price
- ERAS $5.90
- ATRO $20.00
- AVG Volume (30 Days)
- ERAS 1.2M
- ATRO 572.3K
- Earning Date
- ERAS 11-12-2024
- ATRO 11-06-2024
- Dividend Yield
- ERAS N/A
- ATRO N/A
- EPS Growth
- ERAS N/A
- ATRO N/A
- EPS
- ERAS N/A
- ATRO N/A
- Revenue
- ERAS N/A
- ATRO $782,178,000.00
- Revenue This Year
- ERAS N/A
- ATRO $15.70
- Revenue Next Year
- ERAS N/A
- ATRO $6.98
- P/E Ratio
- ERAS N/A
- ATRO N/A
- Revenue Growth
- ERAS N/A
- ATRO 19.95
- 52 Week Low
- ERAS $1.64
- ATRO $14.13
- 52 Week High
- ERAS $3.45
- ATRO $23.74
- Technical
- Relative Strength Index (RSI)
- ERAS 42.73
- ATRO 45.52
- Support Level
- ERAS $2.51
- ATRO $15.90
- Resistance Level
- ERAS $2.68
- ATRO $16.81
- Average True Range (ATR)
- ERAS 0.21
- ATRO 0.49
- MACD
- ERAS -0.04
- ATRO 0.09
- Stochastic Oscillator
- ERAS 14.56
- ATRO 58.79
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About ATRO Astronics Corporation
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.